Quanterix

Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. Its products and services include Simoa Assay Kits, HD-X analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, 2470 Arrayer, Simoa Accelerator Laboratory, Uman NF-Light, and Homebrew -Custom Assay Development. The company was founded by Nicholas J. Naclerio and David R. Walt in April 2007 and is headquartered in Billerica, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Quanterix reports strong Q4 revenue, eyes growth in neurology diagnostics

Quanterix's Q4 performance showcased revenue growth and margin improvement, underpinned by advancements in assay manufacturing and the launch of new tests. The company faces challenges in revenue management and cost control but has opportunities to drive growth through core products and competitive positioning in neurology diagnostics.

Quanterix reports robust Q1 earnings, eyes neuro research growth

Quanterix delivered strong Q1 results with revenue growth and margin improvements, while facing challenges in cash management and meeting revised guidance targets.
The company's focus on neuro research and clinical applications, along with its transformation plan, positions it well for future growth and market leadership.
Analyst inquiries highlighted areas for improvement and clarity, signaling the need for continued strategic communication and operational enhancements.

Quanterix reports robust Q2 earnings, eyes growth in diagnostics market

Quanterix's Q2 performance reflects strong revenue growth and improved profitability.
The company's focus on innovative diagnostics for Alzheimer's and neurological therapies positions it well for future growth.
Despite challenges in leadership transition and addressing specific patient needs, Quanterix remains optimistic about market adoption of blood biomarkers.

Quanterix reports strong Q3 revenue growth and advances in Alzheimer's diagnostics

Quanterix's Q3 performance reflects revenue growth, improved gross margins, and strategic collaborations in blood biomarker testing for Alzheimer's disease.
The company's strengths in expanding platform access, operational efficiency, and multimarker approaches present growth opportunities in diagnostics.
Challenges include meeting revenue growth expectations, maintaining high sensitivity levels in diagnostics, and balancing margin improvements with investments.
Opportunities exist in leveraging partnerships, developing innovative biomarker solutions, and capitalizing on the demand for comprehensive diagnostic tools in healthcare.

Quanterix reports record revenue in Q4 2023, eyes Alzheimer's diagnostics

Quanterix's Q4 2023 performance reflects strong revenue growth, improved margins, and strategic focus on innovation and market expansion.
While challenges in capital allocation and sustaining growth persist, the company's opportunities in menu expansion and Alzheimer's diagnostics are promising.
Overall, Quanterix's financial outlook for 2024 appears positive, with a clear roadmap for growth and continued market penetration.

Quanterix reports revenue growth and innovation drive amidst competition challenges

Quanterix's Q1 2024 performance reflects revenue growth, margin improvement, and innovation in disease detection assays, positioning the company for future success.
Strategic strengths include strong gross margins, successful product launches, and growth in Accelerator Lab services, driving revenue and market presence.
Challenges include competition assessment, margin maintenance, and regulatory milestones, while opportunities exist in innovation, revenue growth, and profitability focus.

Quanterix reports robust Q3 earnings, eyes growth in Alzheimer's diagnostics

Quanterix's strong revenue growth, focus on innovation, and strategic priorities position the company for continued success in the diagnostics market.
While facing challenges in maintaining gross margins and navigating regulatory landscapes, Quanterix has opportunities to drive growth through advanced diagnostics and market expansion.
By balancing customer mix, expanding menu offerings, and investing in new technologies, Quanterix is poised to capitalize on the growing demand for precision medicine and Alzheimer's disease testing.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced that it appointed William (Bill) P. Donnelly to its Board of Directors. Mr. Donnelly brings many years of senior leadership experience in the life science tools industry, including 21 years at Mettler-Toledo International Inc., where he was executive vice president and chief financial officer. Whi.

William P. Donnelly Appointed to Quanterix's Board of Directors

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced that it has appointed Vandana Sriram, CPA, as Chief Financial Officer (CFO), effective August 21, 2023. Sriram replaces Michael Doyle, who has served as the Company's CFO since July 2021. As previously announced, Mike will transition to the role of Executive Director, Finance, focusing on strategi.

Quanterix Appoints Vandana Sriram as Chief Financial Officer

Quanterix Corporation (NASDAQ:QTRX ) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Ed Joyce - Vice President, Investor Relations Masoud Toloue - President & Chief Executive Officer Mike Doyle - Chief Financial Officer Conference Call Participants Puneet Souda - Leerink Partners Kyle Mikson - Canaccord Genuity Matt Sykes - Goldman Sachs Dan Brennan - Cowen Operator Good day, and thank you for standing by. Welcome to the Quanterix Corporation Q2 2023 Earnings Call.

Quanterix Corporation (QTRX) Q2 2023 Earnings Call Transcript

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the three months ended June 30, 2023. Second Quarter Financial Highlights Total revenue was $31.0 million versus prior year second quarter total revenue of $23.5 million, an increase of 32%. Second quarter revenue also increased 9% sequentially driven by increased Accelerator Lab and consumables revenue.

Quanterix Releases Operating Results for Second Quarter 2023

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will be presenting at the Canaccord Genuity 43rd Annual Growth Conference on August 10, 2023 at 12 p.m. EST. The presentation will be available virtually and participants can register here: here. The presentation will be available following the conference on Quanterix's website here:.

Quanterix to Present at Canaccord Genuity 43rd Annual Growth Conference

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced that its Simoa® technology supported a large international study to establish sNfL reference ranges to assess neurological disease activity in children and adolescents, according to a recent study published in The Lancet Neurology. Researchers from the University Hospital Basel and University of B.

Quanterix's Simoa® Technology Powers Large, International Reference Range Study Utilizing Serum Neurofilament Light (sNfL) to Assess Neurological Disease Activity in Pediatric Patients

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will report financial results for the second quarter 2023 before the market opens on Tuesday, August 8, 2023, and will host a webcast and conference call on the same day at 8:30 a.m. E.T. Click here to pre-register for the conference call and obtain your dial-in number and passcode. Interested investors can also acces.

Quanterix to Report Second Quarter 2023 Financial Results on August 8, 2023

Quanterix (QTRX) LucentAD biomarker blood test aims to assist healthcare providers in evaluating patients who show cognitive symptoms consistent with the early signs of AD.

Quanterix (QTRX) Advances in Alzheimer's Diagnosis With LucentAD

Quanterix Corporation (QTRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Quanterix Corporation (QTRX) Surges 13.6%: Is This an Indication of Further Gains?

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced it has launched LucentAD, a test to assist in the evaluation of patients experiencing cognitive symptoms consistent with the early signs of Alzheimer's disease (AD). The LucentAD test, which will be available to healthcare providers as an aid in conjunction with other diagnostic tools, provides cl.

Quanterix Launches LucentAD Biomarker Blood Test to Aid Physician Diagnosis of Alzheimer's Disease in Patients

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will speak at the Goldman Sachs Annual Global Healthcare Conference on June 14, 2023 at 10:40 a.m., PT. The presentation will be available virtually and listeners can register here: https://cc.webcasts.com/gold006/061223a_js/?entity=12_GUSDLRC. The presentation will be available foll.

Quanterix to Participate in Fireside Chat at Goldman Sachs Annual Global Healthcare Conference

Quanterix Corporation (NASDAQ:QTRX ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Mike Doyle - CFO Masoud Toloue - President and CEO Conference Call Participants Alex Vukasin - Canaccord Genuity Operator Good day, and thank you for standing by. Welcome to the Quanterix Corporation First Quarter 2023 Earnings Conference Call.

Quanterix Corporation (QTRX) Q1 2023 Earnings Call Transcript

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the three months ended March 31, 2023. “Our corporate transformation initiated in August 2022 to maximize Quanterix's full potential is on track. We remain confident that we have taken the right steps to build a strong foundation in preparation for future growth,” said Masoud Toloue, President and Chief.

Quanterix Releases Operating Results for First Quarter 2023

Quanterix Corporation (QTRX) Soars 33.7%: Is Further Upside Left in the Stock?

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced it will host a conference call on Tuesday, May 9, 2023, to discuss its first quarter 2023 financial results. The call will begin at 4:30 PM Eastern Time. It will be hosted by Masoud Toloue, the Company's President and Chief Executive Officer, and Michael Doyle, the Company's Chief Financial Officer. Quanterix will issue a pre.

Quanterix's First Quarter 2023 Earnings Conference Call

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced that blood-based NfL measurements provided compelling support for the FDA's accelerated approval of tofersen for treatment of superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a devastating rare genetic form of ALS. This is the first known case in which a blood biomarker was success.

FDA Accelerated Approval of Tofersen Highlights Importance of Blood Neurofilament Light Chain as Surrogate Endpoint in Neurology Therapeutic Trials

Quanterix Corporation (NASDAQ:QTRX ) Q4 2022 Earnings Conference Call March 3, 2023 8:30 AM ET Company Participants Masoud Toloue - CEO Mike Doyle - CFO Conference Call Participants Matt Sykes - Goldman Sachs Puneet Souda - SVB Securities Kyle Mikson - Canaccord Genuity Operator Good day, and thank you for standing by. Welcome to the Quanterix Corporation Q4 2022 Earnings Call.

Quanterix Corporation (QTRX) Q4 2022 Earnings Call Transcript

Quanterix Corporation (QTRX) delivered earnings and revenue surprises of 5.66% and 1.28%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Quanterix Corporation (QTRX) Reports Q4 Loss, Misses Revenue Estimates

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the fourth quarter and twelve months ended December 31, 2022. “Our Simoa technology continues to be on the forefront of research, testing, therapeutic trials and has been an integral part of recent advances in Alzheimer's disease.

Quanterix Releases Operating Results for Fourth Quarter and Full Year 2022; Aligned with Expectations

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will present at Cowen's 43rd Annual Health Care Conference. Quanterix's session will take place on Tuesday, March 7, 2023, at 9:50 a.m. EST and will be made available to attendees and, via webcast, the general public.

Quanterix to Present at Cowen's 43rd Annual Health Care Conference

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced it will host a conference call on Monday, March 6, 2023, to discuss its fourth quarter earnings and full year 2022 financial results. The call will begin at 8:30 AM Eastern Time. It will be hosted by Masoud Toloue, the Company's President and Chief Executive Officer, and Michael Doyle, the Company's Chief Financial Officer.

Quanterix Fourth Quarter Earnings and Full Year 2022 Financial Results Conference Call

BILLERICA, Mass.--( BUSINESS WIRE )--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it has appointed Brian Blaser to its Board of Directors effective as of January 6, 2023.

Quanterix Announces Appointment of Brian Blaser to Board of Directors

BILLERICA, Mass.--( BUSINESS WIRE )--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced the validation of a Laboratory Developed Test (LDT) to quantitatively measure neurofilament light chain (NfL) in serum as an aid in the evaluation of individuals for possible neurodegenerative conditions or other causes of neuronal or central nervous system damage.

Quanterix Expands Laboratory Developed Test Menu with Launch of Neurofilament Light Chain Test

BILLERICA, Mass.--( BUSINESS WIRE )--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will be presenting at the 41st Annual J.P. Morgan Healthcare Conference. Quanterix's session will take place on Thursday, Jan. 12, 2023, at 12 p.m., PST and will be made available to attendees and the general public. In addition to the session, the company will also be hosting one-on-one meetings with institutional investors during the conference.

Quanterix to Present at 41st Annual J.P. Morgan Healthcare Conference

BILLERICA, Mass.--( BUSINESS WIRE )--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that its Simoa® technology has powered important advances in ongoing clinical trials for the treatment of Alzheimer's disease (AD). The findings were presented at the 15th Clinical Trials on Alzheimer's Disease (CTAD) conference held in San Francisco, CA from November 29 to December 2, 2022.

Quanterix's Simoa® Technology Drives Advances in Alzheimer's Disease Research Presented at 2022 Clinical Trials on Alzheimer's Disease (CTAD) Conference

News for Quanterix Stock (QTRX)